Diagnostics.ai
Diagnostics.ai22
About
What does Diagnostics.ai do?
Diagnostics.ai provides automated analysis reporting and quality control for PCR testing. Their CE-IVDR certified AI Analysis Engine offers advanced, error-free AI result analysis for real-time PCR curves, alongside integrated laboratory management and device monitoring tools. They serve leading laboratories.
What is Diagnostics.ai's revenue?
StartupHub estimates Diagnostics.ai's annual revenue at $1.8M (range $1.3M to $4.6M, 68% confidence), based on comparable companies in the sector.
When was Diagnostics.ai founded?
Diagnostics.ai was founded in 2009.
What industry does Diagnostics.ai operate in?
Diagnostics.ai operates in Healthcare, Diagnostics, DNA, MedTech, HealthTech, Molecular Diagnostics.
How many employees does Diagnostics.ai have?
Diagnostics.ai has approximately 10 people on record.
Medbytes provides doctors with a personalized platform for high-impact medical research and news in their specialty.
Provider-supervised peptide therapy, NAD+ support, and cognitive enhancement for cellular renewal, recovery, and healthy aging.
Your health consultation for a pain-free life, offering pain management and therapy solutions.
An AI-powered platform for cancer patients and survivors in Asia to navigate care and understand their diagnosis.
AI-powered personalized sleep coaching and actionable insights for improving sleep quality.
SomaIQ drafts the interpretation and patient explanation for your review, reducing a 90-minute task to five.
Akylmed is developing an AI-powered platform to streamline medical documentation and administrative tasks for healthcare providers.
Longevity and metabolic health platform offering personalized insights and interventions.
An entrant is a company tagged MedTech whose domain was first registered in the window, counted from registry records in the StartupHub directory. 1 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.